Meet Our Team
John Pedersen, President and CEO: John Pedersen joined Augmenix in 2014. Previously he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, John was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.
John earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University. He currently serves on the Board of Directors of Therakos and Clinical Innovations, two privately held medical device companies.
Pat Campbell, CTO: Pat Campbell has over 17 years with the Incept family of companies. He started with Augmenix in 2007. Prior to Augmenix, Pat was the VP of Research and Development at Confluent Surgical, an Incept LLC Company. Previously Pat worked at Focal, Inc., Advanced Cardiovascular Systems, and Symbion, Inc.
Pat holds a PhD and Masters in Bioengineering, and a BS in Mechanical Engineering from the University of Utah. Pat also has over 13 issued U.S. patents.
Ken Knudson, Executive VP of Global Sales and Marketing: Ken Knudson joined Augmenix with 19 years of experience in sales and sales management. Ken was previously VP of Global Sales at Cheetah Medical, and US VP of Sales and European VP of Sales at Bard Electrophysiology. Prior to this, he served as Group Director of Sales for the Boston Scientific Urology and Women’s Health Division.
Ken earned a BA in Economics from the University of Tennessee and an MBA from Boston University.
Tom Guest, VP of Sales Training & Strategic Accounts: Tom Guest has been with Augmenix since 2009. Prior to Augmenix, Tom had 25 years of experience at Johnson & Johnson in various positions that involved sales, marketing, training, sales management, and professional eduation. Tom was the VP of Worldwide Professional Education and a board member at DePuy Orthopaedics, a J&J Company.
Tom also held high level positions at Confluent Surgical, an Incept LLC Company, Focal, Inc., Ethicon Endosurgery, and Ethicon, Inc. Tom received his BS in Business Administration from the University of Richmond.
Nick Svencer, VP of Operations: Nick has been with Augmenix since 2009. He was previously at Brontes Technologies, a 3M Company, Confluent Surgical, an Incept LLC Company, and Analogic Corporation.
Nick earned a BSME and a MS in Engineering Management from Tufts University.
David Inman, VP of Finance: Dave Inman has been with Augmenix since 2016. Prior to Augmenix, Dave was with Haemonetics Corporation as head of Global Financial Planning & Analysis, and previously had held Finance, Marketing, New Business Development, and Strategic Planning roles at Boston Scientific Corporation and Staples, Inc. Dave earned a BA in Economics from the University of Pennsylvania, and an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.